Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

Aim: To describe the evolution of regorafenib use, since its approval, in patients with previously treated metastatic colorectal cancer (mCRC) in routine clinical practice in Spain. Methods: We extracted patient characteristics, dosing, safety and efficacy data for the Spanish cohorts of the CORRECT...

Descripción completa

Detalles Bibliográficos
Autores: Cervantes, A, Tabernero, J, Garcia-Carbonero, R, Sastre, J, Feliu, J, Guillén-Ponceg, C, Paredes, BG, Carral, A, Munoz, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p18369
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/18369
Access Level:acceso abierto
Palabra clave:evolution
clinical trial
metastatic colorectal cancer
real-world evidence
regorafenib
Spain
id ES_d202fcc331f67d603d70cbe9d3c715d2
oai_identifier_str oai:incliva.fundanetsuite.com:p18369
network_acronym_str ES
network_name_str España
repository_id_str
spelling Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidenceCervantes, ATabernero, JGarcia-Carbonero, RSastre, JFeliu, JGuillén-Ponceg, CParedes, BGCarral, AMunoz, Jevolutionclinical trialmetastatic colorectal cancerreal-world evidenceregorafenibSpainAim: To describe the evolution of regorafenib use, since its approval, in patients with previously treated metastatic colorectal cancer (mCRC) in routine clinical practice in Spain. Methods: We extracted patient characteristics, dosing, safety and efficacy data for the Spanish cohorts of the CORRECT and CONSIGN trials, and the real-world CORRELATE study. Results: The Spanish cohorts represented 10.7-13.8% of the global cohorts. Efficacy and safety in the Spanish cohorts reflected findings from the global cohorts, with evidence of a flexible dosing approach being adopted in routine clinical practice. Conclusion: Regorafenib use in patients with mCRC has evolved in the real-world setting, emphasizing the need for further research evaluating dosing patterns that can optimize clinical outcomes in these patients.TAYLOR & FRANCIS LTD2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/18369Future OncologyISSN: 14796694ISSNe: 17448301reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p183692026-06-07T16:35:31Z
dc.title.none.fl_str_mv Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
title Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
spellingShingle Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
Cervantes, A
evolution
clinical trial
metastatic colorectal cancer
real-world evidence
regorafenib
Spain
title_short Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
title_full Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
title_fullStr Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
title_full_unstemmed Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
title_sort Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
dc.creator.none.fl_str_mv Cervantes, A
Tabernero, J
Garcia-Carbonero, R
Sastre, J
Feliu, J
Guillén-Ponceg, C
Paredes, BG
Carral, A
Munoz, J
author Cervantes, A
author_facet Cervantes, A
Tabernero, J
Garcia-Carbonero, R
Sastre, J
Feliu, J
Guillén-Ponceg, C
Paredes, BG
Carral, A
Munoz, J
author_role author
author2 Tabernero, J
Garcia-Carbonero, R
Sastre, J
Feliu, J
Guillén-Ponceg, C
Paredes, BG
Carral, A
Munoz, J
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv evolution
clinical trial
metastatic colorectal cancer
real-world evidence
regorafenib
Spain
topic evolution
clinical trial
metastatic colorectal cancer
real-world evidence
regorafenib
Spain
description Aim: To describe the evolution of regorafenib use, since its approval, in patients with previously treated metastatic colorectal cancer (mCRC) in routine clinical practice in Spain. Methods: We extracted patient characteristics, dosing, safety and efficacy data for the Spanish cohorts of the CORRECT and CONSIGN trials, and the real-world CORRELATE study. Results: The Spanish cohorts represented 10.7-13.8% of the global cohorts. Efficacy and safety in the Spanish cohorts reflected findings from the global cohorts, with evidence of a flexible dosing approach being adopted in routine clinical practice. Conclusion: Regorafenib use in patients with mCRC has evolved in the real-world setting, emphasizing the need for further research evaluating dosing patterns that can optimize clinical outcomes in these patients.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/18369
url https://incliva.portalinvestigacion.com/publicaciones/18369
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv TAYLOR & FRANCIS LTD
publisher.none.fl_str_mv TAYLOR & FRANCIS LTD
dc.source.none.fl_str_mv Future Oncology
ISSN: 14796694
ISSNe: 17448301
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420312932646912
score 15,812429

Similares en LA Referencia